Association between Hypomagnesemia, COVID-19, Respiratory Tract and Lung Disease
Gavino Faa1, 2, Luca Saba3, Daniela Fanni1, 2, Goce Kalcev4, *, Mauro Carta5
Identifiers and Pagination:Year: 2021
First Page: 43
Last Page: 45
Publisher ID: TORMJ-15-43
Article History:Received Date: 15/1/2021
Revision Received Date: 26/4/2021
Acceptance Date: 7/6/2021
Electronic publication date: 17/09/2021
Collection year: 2021
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The complexity of COVID-19 is also related to the multiple molecular pathways triggered by SARS-CoV-2, which is able to cause type I pneumocyte death, trigger intravascular coagulation, interfere with the renin-angiotensin system, dysregulate iron metabolism, ending with the insurgence of a cytokine storm which may lead to death. Old adults with obesity, hypertension, and diabetes are among the high-risk category groups more prone to SARS-CoV-2 infection. Magnesium has been reported to play a major role both in physiology and in pathology, particularly in elderly people, regulating cytotoxic functions of natural killer (NK) cells and CD8+ T lymphocytes. In spite of the absence of controlled trials, the possibility of magnesium supplementation for supportive treatment in patients with COVID-19 should be encouraged. This could be useful in all phases of the COVID-19 disease.